Pilocarpine + Timolol (Pilocarpinum + Timololum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Ophthalmic products

Beta-blockers

M-holinomimetiki

Included in the formulation
  • Pilotimol®
    drops d / eye 
    SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products     Russia
  • Pilotimol® mini
    drops d / eye 
    SYNTHESIS, JSC Joint-stock Kurgan Society of Medical Preparations and Products     Russia
  • Fotil®
    drops d / eye 
    Santen, AO     Finland
  • Fotil® forte
    drops d / eye 
    Santen, AO     Finland
    • АТХ:

    S.01.E.B.51   Pilocarpine in combination with other drugs

    Pharmacodynamics:

    Combined drug.

    Pilocarpine

    M-cholinomimetic, when instillation in the conjunctival sac causes miosis and spasm of accommodation, lowers the intraocular pressure, by reducing the ciliary muscle and the muscle of the iris, which changes the physical structure of the trabecular tissue, widens the angle of the anterior chamber of the eye and facilitates the outflow of aqueous humor. The drug lasts from 4 to 14 hours.

    Timolol

    beta-blocker, prevents binding sympathomimetic neuromediators with β1 and β2 adrenoreceptors in the ciliary body, which leads to a decrease in the production of aqueous humor and a decrease in intraocular pressure.

    Pharmacokinetics:

    Pilocarpine penetrates the cornea, concentration in watery moisture is achieved after 30 minutes.It binds to the eye tissues, which increases the half-life from 1.5 to 2.5 hours. The effect of reducing the intraocular pressure lasts up to 24 hours. It is not metabolized in the aqueous humor, it is released together with it.

    Timolol prolongs the half-life of pilocarpine. Partially absorbed through the conjunctiva, the mucous membranes of the lachrymal tract and nose. In therapeutic doses does not cause a systemic effect on the body.

    Indications:

    It is used to treat open and closed angle glaucoma, secondary glaucoma, with increased intraocular pressure after ophthalmic operations.

    ICD-10

    VII.H40-H42.H40.0   Suspicion of glaucoma

    VII.H40-H42.H40.1   Primary open angle glaucoma

    VII.H40-H42.H40.2   Primary angle-closure glaucoma

    VII.H40-H42.H40.3   Glaucoma secondary posttraumatic

    VII.H40-H42.H40.5   Glaucoma secondary due to other eye diseases

    VII.H40-H42.H40.4   Glaucoma secondary due to inflammatory disease of the eye

    Contraindications:

    Iritis, iridocyclitis, corneal dystrophy, rhinitis, cardiogenic shock, chronic obstructive pulmonary disease, individual intolerance, children under 18 years.

    Carefully:

    Violations of cerebral circulation, retinal detachment, thyrotoxicosis, diabetes mellitus, hypoglycemia, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    1 drop in the conjunctival sac 2 times a day. After achieving a stable decrease in intraocular pressure - 1 drop every 1 time per day.

    Side effects:

    Spasm of ciliary muscle, burning, pain in the eyes, induced myopia, conjunctival hyperemia. With prolonged use: iris cyst, retinal detachment, lens opacity, spot keratitis, retinal anesthesia.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    Care should be taken with care when driving vehicles and working with moving mechanisms, especially at night.

    Patients who use contact vision correction,Before using drops, it is recommended to remove soft lenses and wear them only after 15 minutes.

    Instructions
    Up